Avicanna Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVCNF research report →
About the company
Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions.
- CEO
- Aras Azadian Mba
- IPO
- 2021
- Employees
- 87
- HQ
- Toronto, ON, CA
Price Chart
- Market Cap
- $11.20M
- P/E
- -3.92
- P/S
- 0.58
- P/B
- 3.69
- EV/EBITDA
- -5.59
- Div Yield
- 0.00%
- Gross Margin
- 51.34%
- Op Margin
- -12.95%
- Net Margin
- -13.90%
- ROE
- -116.09%
- ROIC
- -25.02%
- Revenue
- $25.46M · -0.01%
- Net Income
- $-2,841,896 · 21.44%
- EPS
- $-0.02 · 31.49%
- Op Income
- $-2,713,780
- FCF YoY
- 51.32%
- 52W High
- $0.24
- 52W Low
- $0.07
- 50D MA
- $0.10
- 200D MA
- $0.14
- Beta
- 0.33
- Avg Volume
- 101.33K
Get TickerSpark's AI analysis on AVCNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AVCNF coverage
Recent articles, reports, and earnings notes.
No research on AVCNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVCNF report →Similar companies
Peers in the same neighborhood.